These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

694 related items for PubMed ID: 16869719

  • 1. Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230).
    Eastell R, Hannon RA, Cuzick J, Dowsett M, Clack G, Adams JE, ATAC Trialists' group.
    J Bone Miner Res; 2006 Aug; 21(8):1215-23. PubMed ID: 16869719
    [Abstract] [Full Text] [Related]

  • 2. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses.
    Baum M, Buzdar A, Cuzick J, Forbes J, Houghton J, Howell A, Sahmoud T, ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group.
    Cancer; 2003 Nov 01; 98(9):1802-10. PubMed ID: 14584060
    [Abstract] [Full Text] [Related]

  • 3. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates.
    Confavreux CB, Fontana A, Guastalla JP, Munoz F, Brun J, Delmas PD.
    Bone; 2007 Sep 01; 41(3):346-52. PubMed ID: 17618847
    [Abstract] [Full Text] [Related]

  • 4. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230.
    Eastell R, Adams JE, Coleman RE, Howell A, Hannon RA, Cuzick J, Mackey JR, Beckmann MW, Clack G.
    J Clin Oncol; 2008 Mar 01; 26(7):1051-7. PubMed ID: 18309940
    [Abstract] [Full Text] [Related]

  • 5. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
    Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Kainberger F, Kässmann H, Piswanger-Sölkner JC, Seifert M, Ploner F, Menzel C, Dubsky P, Fitzal F, Bjelic-Radisic V, Steger G, Greil R, Marth C, Kubista E, Samonigg H, Wohlmuth P, Mittlböck M, Jakesz R, Austrian Breast and Colorectal Cancer Study Group (ABCSG).
    Lancet Oncol; 2008 Sep 01; 9(9):840-9. PubMed ID: 18718815
    [Abstract] [Full Text] [Related]

  • 6. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.
    Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS, ATAC Trialists' Group.
    Lancet; 2008 Sep 01; 365(9453):60-2. PubMed ID: 15639680
    [Abstract] [Full Text] [Related]

  • 7. Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial.
    Goss PE, Hershman DL, Cheung AM, Ingle JN, Khosla S, Stearns V, Chalchal H, Rowland K, Muss HB, Linden HM, Scher J, Pritchard KI, Elliott CR, Badovinac-Crnjevic T, St Louis J, Chapman JA, Shepherd LE.
    Lancet Oncol; 2014 Apr 01; 15(4):474-82. PubMed ID: 24636210
    [Abstract] [Full Text] [Related]

  • 8. Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study.
    Coleman RE, Banks LM, Girgis SI, Kilburn LS, Vrdoljak E, Fox J, Cawthorn SJ, Patel A, Snowdon CF, Hall E, Bliss JM, Coombes RC, Intergroup Exemestane Study group.
    Lancet Oncol; 2007 Feb 01; 8(2):119-27. PubMed ID: 17267326
    [Abstract] [Full Text] [Related]

  • 9. Long-term effects of anastrozole on bone mineral density: 7-year results from the ATAC trial.
    Eastell R, Adams J, Clack G, Howell A, Cuzick J, Mackey J, Beckmann MW, Coleman RE.
    Ann Oncol; 2011 Apr 01; 22(4):857-862. PubMed ID: 20929964
    [Abstract] [Full Text] [Related]

  • 10. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17.
    Perez EA, Josse RG, Pritchard KI, Ingle JN, Martino S, Findlay BP, Shenkier TN, Tozer RG, Palmer MJ, Shepherd LE, Liu S, Tu D, Goss PE.
    J Clin Oncol; 2006 Aug 01; 24(22):3629-35. PubMed ID: 16822845
    [Abstract] [Full Text] [Related]

  • 11. Anastrozole as adjuvant therapy for early-stage breast cancer: implications of the ATAC trial.
    Buzdar A.
    Clin Breast Cancer; 2003 Apr 01; 4 Suppl 1():S42-8. PubMed ID: 12756078
    [Abstract] [Full Text] [Related]

  • 12. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial.
    Arimidex, Tamoxifen, Alone or in Combination Trialists' GroupUniversity of Texas, MD Anderson Cancer Center, Houston, TX, USA., Buzdar A, Howell A, Cuzick J, Wale C, Distler W, Hoctin-Boes G, Houghton J, Locker GY, Nabholtz JM.
    Lancet Oncol; 2006 Aug 01; 7(8):633-43. PubMed ID: 16887480
    [Abstract] [Full Text] [Related]

  • 13. A study of the effects of the aromatase inhibitors anastrozole and letrozole on bone metabolism in postmenopausal women with estrogen receptor-positive breast cancer.
    McCaig FM, Renshaw L, Williams L, Young O, Murray J, Macaskill EJ, McHugh M, Hannon R, Dixon JM.
    Breast Cancer Res Treat; 2010 Feb 01; 119(3):643-51. PubMed ID: 19941160
    [Abstract] [Full Text] [Related]

  • 14. Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial.
    Van Poznak C, Hannon RA, Mackey JR, Campone M, Apffelstaedt JP, Clack G, Barlow D, Makris A, Eastell R.
    J Clin Oncol; 2010 Feb 20; 28(6):967-75. PubMed ID: 20065185
    [Abstract] [Full Text] [Related]

  • 15. Effects of exemestane, anastrozole and tamoxifen on bone mineral density and bone turnover markers in postmenopausal early breast cancer patients: results of N-SAS BC 04, the TEAM Japan substudy.
    Aihara T, Suemasu K, Takei H, Hozumi Y, Takehara M, Saito T, Ohsumi S, Masuda N, Ohashi Y.
    Oncology; 2010 Feb 20; 79(5-6):376-81. PubMed ID: 21430407
    [Abstract] [Full Text] [Related]

  • 16. Changes in bone turnover and in bone mass in women with breast cancer switched from tamoxifen to exemestane.
    Gonnelli S, Cadirni A, Caffarelli C, Petrioli R, Montagnani A, Franci MB, Lucani B, Francini G, Nuti R.
    Bone; 2007 Jan 20; 40(1):205-10. PubMed ID: 16904960
    [Abstract] [Full Text] [Related]

  • 17. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
    Margolese RG, Cecchini RS, Julian TB, Ganz PA, Costantino JP, Vallow LA, Albain KS, Whitworth PW, Cianfrocca ME, Brufsky AM, Gross HM, Soori GS, Hopkins JO, Fehrenbacher L, Sturtz K, Wozniak TF, Seay TE, Mamounas EP, Wolmark N.
    Lancet; 2016 Feb 27; 387(10021):849-56. PubMed ID: 26686957
    [Abstract] [Full Text] [Related]

  • 18. Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the 'Arimidex and tamoxifen alone or in combination' (ATAC) trial.
    Dowsett M, Cuzick J, Howell A, Jackson I, ATAC Trialists' Group.
    Br J Cancer; 2001 Aug 03; 85(3):317-24. PubMed ID: 11487258
    [Abstract] [Full Text] [Related]

  • 19. The ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial: an update.
    Buzdar AU.
    Clin Breast Cancer; 2004 Sep 03; 5 Suppl 1():S6-S12. PubMed ID: 15347433
    [Abstract] [Full Text] [Related]

  • 20. Data from the Arimidex, tamoxifen, alone or in combination (ATAC) trial: implications for use of aromatase inhibitors in 2003.
    Buzdar AU.
    Clin Cancer Res; 2004 Jan 01; 10(1 Pt 2):355S-61S. PubMed ID: 14734491
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.